Background. Low bone mineral density (BMD) is common among patients infected with human immunodeficiency virus (HIV) and present in higher rates in black subjects. This study assessed vitamin D levels in HIV cases versus noninfected matched controls to determine if deficiency was associated with BMD and HIV clinical outcomes.
Vitamin D deficiency (VDD) is common in both the general population and human immunodeficiency virus (HIV)-infected populations in the United States. The National Health and Nutrition Examination Survey (NHANES) noted lower serum 25-OH vitamin D levels in blacks compared to whites [1] . The Study to Understand the Natural History of HIV and AIDS in the Era of Effective Therapy (SUN) found deficiency to be highly prevalent (88.5%) in black HIVinfected persons. Risk factors included a lack of exercise, race, renal insufficiency, and efavirenz containing antiretroviral regimens [2] . Significantly lower vitamin D levels have been found in patients receiving protease inhibitors (PIs) or nonnucleoside reverse transcriptase inhibitors (NNRTIs) when compared to treatment-naive HIV-infected controls [3] .
Osteoporosis is 3 times more prevalent in HIV-infected men compared to those without HIV [4] . Low body mass index (BMI), higher HIV viral load (VL), and increased duration of HIV infection have been associated with the presence of bone abnormalities [5] . Bone-related complications such as fractures have been reported at higher rates in HIV patient populations [6, 7] .
During 2001-2, a cross-sectional study evaluated bone mineral density in 271 HIV-infected military beneficiaries enrolled in the HIV Natural History Study (NHS). Rates of osteopenia and osteoporosis were found to be 40% and 6.4%, respectively. Black ethnicity was significantly associated with low bone mineral density (BMD). The multivariable analysis of sociodemographic and clinical factors did not explain the observed ethnic disparity [8] . The purpose of the current study was to retrospectively analyze vitamin D levels and to use subsequent NHS follow-up data to determine if VDD was associated with low BMD or HIV-related outcomes.
MATERIALS AND METHODS
A hologic QDR 4500A bone mineral densitometer provided DEXA scans of the proximal femur and lumbar spine. Data were collected at the time of DEXA using coordinator administered questionnaires screening alcohol and smoking history, weight, exercise, lactose intolerance, concomitant medical disease, medication use, duration of HIV infection, and antiretroviral exposure. Inadvertent destruction of the original copies required questionnaire items to be reassessed among participants (n = 211) at follow-up clinical visits; a conventional statistical method for missing data was used to include the ( presumed) random subsample not reassessed. NHS data repository review provided information regarding HIV-related factors [9, 10] .
The active duty subset of the HIV-infected cohort (n = 205) was matched to an uninfected cohort from the DoDSR. Two predeployment HIV-uninfected military controls were matched to each case according to age ± 3 years, sex, race, season, date of serum collection ± 3 years, and first 3 digits of the zip code of the military unit. No clinical information was available regarding the matched controls.
Banked serum samples from the cohort were tested to determine 25OH vitamin D, parathyroid hormone, and total/ free testosterone levels at the time of DEXA. Vitamin D levels were determined using the LIAISON 25-OH vitamin D immunoluminometric assay on serum samples from the cases at the time of DEXA and 6 or 18 months prior and on serum samples from each of the 2 matched controls. Averages of the 2 seasonally distinct case results and the 2 matched control results were used for the statistical analysis to reduce confounding from seasonal variation [11, 12] ; this approach was the best possible given the limited capability of the DoDSR to provide multiple specimens from different seasons for a single control. Using averages resulted in a 1:1 exposure ratio, although controls were identified in a 2:1 ratio. Testosterone level was determined using an ELECSYS testosterone electrochemiluminescence immunoassay and free testosterone was calculated [13] . Parathyroid hormone was measured using an ELECSYS radioimmunoassay.
Review of the NHS data repository provided information regarding zip codes at time of DEXA, cumulative antiretroviral exposure, clinical outcomes, and laboratory data (comprehensive metabolic studies, lipids, CD4 count, VL, and hepatitis B/ C serologies). Latitude was determined using online databases at www.zipinfo.com ( primary) and http://federalgovernmentzipcodes.us. Clinical outcomes after DEXA were reviewed including death, hospitalizations, decline in CD4 count <200 cells/mm 3 , and AIDS-defining conditions [14] .
Data Variable Definitions
VDD was defined as an average value of <20 ng/mL [15] . World Health Organization (WHO) criteria were used defining osteopenia as a BMD t score between −1 and −2.5 and osteoporosis as a t score of −2.5 or lower compared to a race/ sex matched 30 year-old population [16] . CD4 counts and VL measurements at seroconversion and DEXA were the closest measurement within a ± 90-day window. Duration of antiretroviral therapy (ART) was defined as the sum of continuous time on regimens in months. Death and hospitalization were identified using first-time diagnostic codes for these events in the NHS data repository during 8 years of follow-up after the DEXA. Decline in CD4 was defined as having 2 occurrences of CD4 <200 cells/mm 3 within 1 year. AIDS-defining illnesses were defined using the 1993 Centers for Disease Control and Prevention (CDC) classification [14] . Chronic hepatitis B was defined as having a repeatedly positive HBsAg over >6 months and chronic hepatitis C as having a single positive anti-HCV before the date of DEXA.
Statistical Methods
Baseline characteristics were tabulated using proportions for discrete-valued variables and medians for continuous variables (interquartile range [IQR] ) calculated for the overall study population and individual vitamin D groups. Mean and standard deviation are reported for variables with a normal distribution. P values were computed using indicated tests. Fisher exact or χ 2 tests were used for categorical variables. Wilcoxon tests were used for univariate analysis of continuous variables that did not meet normality criterion (Shapiro-Wilks test; Pvalue >.05 within each group); t tests were used for those that met criterion. Logistic regression was used to explore possible risk factors for low BMD including VDD. To include all available risk factor information for the subset of participants whose questionnaires were not readministered, a method for handling missing covariates was employed (EM algorithm by the method of weights, a one-time model-fitting alternative to multiple imputation) [17] . A stepwise approach was used to select the final model [18] . Analyses were conducted using R version 2, SAS version 9.2, and StatXact version 8; study design used PASS 2008.
RESULTS
Baseline characteristics of HIV-infected subjects and potential factors associated with VDD are summarized in (IQR, 336-704), whereas median VL was 2.6 log 10 copies/mL (IQR, 2.6-3.8). The subjects lived primarily along the east coast although cases were distributed throughout the United States ( Figure 1 ). A majority of HIV-infected cohort members (187 of 270) with available serum samples were VDD: 69% (95% confidence interval [CI], 63%-75%) versus 302 of 509 (59%) non-HIV infected controls. Race was significantly associated with VDD (P <.001; Table 1 ); blacks tended to be disproportionately deficient. Higher body mass index (BMI) and cholesterol were associated with VDD. Latitude was not significantly associated with deficiency (P = .244), although generally lower median levels were noted at higher latitudes ( Figure 1 ). Several medications, including antiretroviral agents, were analyzed relative to deficiency. Subanalysis of cumulative exposure to specific classes of antiretrovirals (NRTI, NNRTI, and PI including ritonavir) revealed no significant associations to deficiency. Efavirenz exposure was not associated with deficiency (P = .161). Only 13 subjects had previous exposure to tenofovir (duration, 3.2 months; IQR, 1.8-5.7) at time of DEXA. To assess the association of VDD to HIV infection adjusting for demographics, samples of an active duty HIV-infected subcohort (n = 205) were matched using DoDSR controls. A total of 189 (92.2%) HIV-infected cases had matched control serum samples and 165 (80.5%) had 2 matched controls (n = 330 control serum samples tested). Matched case-control comparisons of vitamin D levels within each racial group are summarized in Figure 2 ; only those sets whose season-averaged levels were discrepant were informative to our chosen measure of association (OR for paired binary data). HIV cases appeared to be at greater risk of VDD compared to controls across racial groups but not to a statistically significant degree (likelihood ratio test, P = .15; adjusted OR, 1.46; 95% CI, .87-2.45).
Risk factors for low BMD were also analyzed. A family history of osteoporosis was reported in 15 (12%) VDD HIVinfected subjects versus 14 (22%) nondeficient (P = .11). A self-reported history of fracture was noted in 38 (31%) deficient subjects versus 20 (38%) of the nondeficient (P = .43). There was no association between VDD and low BMD among HIV-infected cases for either race. Spearman correlation coefficients did not show a significant relationship between vitamin D levels and DEXA t-scores: the hip at 0.33 (95% CI, −.04, .26) or the spine at 0.077 (95% CI, −.002, .29). Elevated parathyroid hormone levels were associated with lower vitamin D levels; among n = 257 participants with both measurements Spearman correlation coefficient was estimated to be -0.35 (95% CI, −.45, −.24). Several clinical characteristics were associated with low BMD (see Table 2 ). Both ethnicity and lower BMI at time of DEXA were positively associated with low BMD (unadjusted P values of .017 and .037, respectively). Alcohol use (>2 drinks daily) was a risk factor (adjusted P value, .015), as was exercising <3 days per week (unadjusted P value, <.001) and family history of osteoporosis (unadjusted P = .001). Logistic regression adjusting for multiple predictors at once confirmed all of these as risk factors for low BMD. Table 2 lists all factors found significant in a stepwise multiple predictor model fitting that included the 4-category vitamin D levels using clinical cutpoints; a single term indicating VDD (<20 ng/mL) was substituted for ease of interpretation in the final step. Interestingly, lactose intolerance (unadjusted P = .045) was not significant in this final multiple predictor model.
Factors that were not significantly associated with low BMD included smoking; HIV-related factors including CD4 and VL at DEXA, CD4 nadir, duration of HIV infection, AIDS defining conditions; chronic hepatitis B or C; diabetes mellitus, hyperthyroidism; self-reported fracture; and medication use to include calcium, bisphosphonates, steroids, thyroid hormone, diuretics, and proton pump inhibitors and H2 blockers (some data not shown). An analysis of cumulative exposure to antiretrovirals as a whole and segregated by individual classes did not demonstrate a significant relationship to low BMD. Time on efavirenz was not related to low BMD. A total of 18 of 229 (7.9%) male subjects were found to have total testosterone levels <280 ng/mL. In sum, 10 of 18 (55.6%) were white and 8 We analyzed VDD relative to subsequent all-cause mortality, hospitalizations, respiratory disease, non-skin malignancies, decline in CD4, and subsequent clinical AIDS events. The study did not have sufficient power to detect relationships at a 5% significance level between VDD and clinical outcomes other than bone loss while accounting for differential amounts of follow-up. Descriptive information is presented in Table 3 .
DISCUSSION
VDD was highly prevalent in our generally healthy HIVinfected and antiretroviral exposed black population (74%) but equally prevalent in a healthy black active duty control group (78%). Single nucleotide polymorphism (SNP)-related genetic variation in vitamin D receptors have been proposed as an etiology for racial predisposition [19] . Two other studies have suggested less deficiency in HIV-infected subjects [20] . Our observation clarifies previously published variable results regarding vitamin D levels in male HIV patients and supports ethnicity as a risk factor for deficiency [1] . Vitamin D metabolism may be affected by exposure to specific classes of antiretrovirals, although no such associations were found in our cohort [21] . Exposure to efavirenz, black ethnicity, and lack of exercise were identified as risk factors in the aforementioned SUN cohort [2] . In a Swiss HIV cohort, vitamin D levels were higher in white patients and lower in those with active NNRTI use [22] . In HIV-infected and uninfected women in the United States, black patients had the highest rates of VDD with recent PI use as a predictor [23] . Low vitamin D levels were also seen in the HIV black volunteers screened in the MONET trial; greater increases in vitamin D levels were noted in those who discontinued efavirenz in favor of a darunavir [24] . Although longitudinal studies have demonstrated a 5 ng/mL reduction in 25OH vitamin D within 6-12 months of starting efavirenz, it is not known whether this effect is attenuated over time [25] . In our analysis 103 persons were on efavirenz at time of DEXA, evenly distributed by race, and we used a 20 ng/mL level for defining VDD (some studies finding an efavirenz association noted it with severe deficiency <10 ng/mL and in white predominant populations) [2, 22] . Our observations may differ because of insufficient sample size to determine a difference, overall high rates of VDD, and a population that was 71% persons of color.
The primary outcome in our study was skeletal: VDD invoked as an explanation for racial disparity in low BMD; however, our results did not support VDD as an etiology. VDD has been associated with bone loss in patient populations that have multiple predisposing factors for reduced BMD such as hemophiliacs [26] . HIV patients likely have significant Figure 2 . Active duty HIV-infected case versus matched non-HIV infected control season-averaged vitamin D levels within race categories. Race groups differ qualitatively in association measured by paired-data odds ratios (ORs); given this as well as only 59 case-control matched pairs with discordant vitamin D status contribute to an overall OR, there is inadequate precision to rule out "no association" (OR, 1.46; 95% confidence interval, .87-2.45). Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus.
abnormalities in the bone remodeling process. A meta-analysis found 884 (67%) HIV patients had reduced BMD with increased risk noted in those exposed to PIs. Few studies included in this analysis adjusted for variables such as disease severity or treatment duration [27] . Time on PIs, time on tenofovir, and current use of PIs have been suggested as risk The hip or spine t score <−1 was compared to the race-and sex-matched 30-year-old population. All participants with available data were included (n ≤ 271), applying EM by methods of weights where noted (*). * is symbol used in table to show EM analysis used. Note that not all predictors are included in both columns; only those predictors whose significance warranted inclusion in the stepwise model-fitting process were used [15] . This is true for lactose intolerance, whereas the categorized serum vitamin D levels were maintained as a 4-level categorical variable until the final (refitted) model. factors for low BMD [28] . Other studies have not revealed an association between HAART and BMD; bone loss has been reported in therapy-naive HIV patients [5, 29] . HAART and PIs as a class were not associated with low BMD in our cohort, and tenofovir use was minimal. The role of VDD and bone loss in HIV-infected populations remains to be defined. In 74 HIV-infected cases no differences in vitamin D levels were noted between those with and without osteopenia; those without previous HAART exposure had lower vitamin D [29] .
Although risk factors such as lower BMI, less exercise, increased alcohol use, black rather than white race, and a family history of osteoporosis were significantly associated with low BMD in our cohort; VDD was not. Lactose intolerance was identified as a risk factor for VDD in another HIV cohort [30] . Blacks generally report less dairy consumption and are more likely to experience physical symptoms of discomfort after ingesting dairy products [31] . Dairy foods are common sources of calcium/vitamin D, and reduced intake (regardless of selfreported lactose intolerance) could impact racial disparity in BMD.
There are few reports of extraskeletal clinical outcomes related to VDD in HIV-infected populations. Higher incidence rates of AIDS and death have been seen in patients with baseline 25-OH vitamin D levels <12 ng/mL [32] . Studies in non-HIV patients indicate that mortality from malignancy and cardiovascular disease varies according to increasing distance from the equator, suggestive of vitamin D effect [33] . Vitamin D has immune modulating properties ( perhaps through autophagy), and deficiency has been linked to viral respiratory illnesses and tuberculosis [34, 35] . In HIV patients from Tanzania, low vitamin D status correlated with progression to WHO HIV disease stage III, although no significant relationship between vitamin D and CD4 count was noted. Higher vitamin D levels appeared to protect against all-cause mortality and anemia in infected women [36] . The modest number of events and lack of clearly delineated follow-up periods (eg, timing of DEXA/vitamin D) limited our estimation of interpretable clinical outcomes.
There are other limitations to our study. The cohort was geographically restricted to latitudes particularly at risk for VDD. Recall bias could have impacted data obtained regarding self-reported histories of osteoporosis and fractures in a population undergoing DEXA screening. The study design was subject to selection bias. This was an overall healthy HIVinfected population treated with antiretrovirals, with excellent access to medical care. The effect of lack of antiretroviral treatment could not be evaluated. Furthermore, tenofovir, with potentially deleterious effects on bone mineralization, was not generally available (approved by the Food and Drug Administration in 2001). Prospective data on the development of fractures and follow-up DEXA scan results were not collected. Data on vitamin D supplementation was not available nor was systematic assessment of subsequent supplementation in osteopenic patients, although it is notable that those identified at the time of DEXA as osteoporotic were referred for bisphosphonate therapy. Finally, the method of obtaining matched but de-identified control serum samples from the DoDSR did not allow for clinical information to be gathered on controls.
Strengths of our study are that the cohort was a relatively large population of color with a low rate of comorbidities that could potentially influence vitamin D and bone metabolism, generally stable socioeconomic status, and equal access to care. Use of a matched noninfected control group to assess the association of VDD with HIV infection strengthens the study. We were able to evaluate clinical outcomes nearly a decade after vitamin D levels were assessed. Our results support targeted behavioral interventions regarding alcohol reduction, exercise, and strategies to accommodate lactose intolerance and promote dietary dairy intake to maintain bone health in HIV populations.
CONCLUSIONS
In this predominantly black male cohort of HIV-infected patients, low BMD was highly prevalent. Risk factors related to low BMD were confirmed, although low BMD did not appear to be associated with VDD. Antiretroviral exposure did not impact bone density or the presence of deficiency. Given the limited data available we could not determine the relationship between tenofovir exposure and VDD or low BMD. With the data available we did not identify a relationship of VDD to HIV disease progression or all-cause mortality. Well-designed studies to evaluate vitamin D supplementation's effect on serum vitamin D levels and low BMD over time, as well as on HIV disease in the presence of antiretroviral therapy, should be conducted before empirically providing supplementation in an attempt to prevent adverse outcomes.
Notes

